Skip to content
QuantConomy

Bicara Therapeutics Inc

BCAX

Latest QuantConomy context for BCAX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

Bicara Therapeutics Inc

QuantConomy has a structured record for BCAX. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
BCAX
Name
Bicara Therapeutics Inc
Coverage
3 market/data records
Sources
fmp alphavantage alpaca sec nasdaq
Latest signal rows

Recent signals for BCAX

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
fundamental
eps change
bearish
71
Jul 11, 12:00 AM BCAX (Q1 2026, diluted eps): EPS declined 38.8% ($-0.67 → $-0.93). [sequential period basis, bearish signal]
fundamental
net income change
very bearish
76
Jul 11, 12:00 AM BCAX (Q1 2026, net income): declined 54.7% (-$36.33M → -$56.21M). [sequential period basis, very bearish signal]
fundamental
operating income change
very bearish
76
Jul 11, 12:00 AM BCAX (Q1 2026, operating income): declined 48.1% (-$40.68M → -$60.24M). [sequential period basis, very bearish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

PRICE signals are experimental while directional effectiveness is re-baselined under the current scoring ruler. Composite weighting stays neutral until both bullish and bearish cohorts each reach 100 observations across 5 UTC days. Signals are served raw here; do not use them as standalone trade advice.

Market coverage

Market Exchange Source Asset record
BCAX NASDAQ fmp Bicara Therapeutics Inc. Common Stock
BCAX NASDAQ alphavantage Bicara Therapeutics Inc
BCAX NASDAQ alpaca Bicara Therapeutics Inc. Common Stock

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
0
Rows
20
Date Insider Role Type Shares Price Value Filing
Jul 10, 2026 Mazumdar Claire Chief Executive Officer exercise 10,000 $3.79 $37,898 4 on EDGAR
Jul 8, 2026 Cohlhepp Ryan President and COO exercise 18,750 $3.79 $71,059 4 on EDGAR
Jul 8, 2026 Hyep Ivan Chief Financial Officer exercise 12,500 $3.79 $47,373 4 on EDGAR
Jun 9, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner grant 19,475 — — 4 on EDGAR
Jun 9, 2026 Mazumdar-Shaw Kiran Insider grant 19,475 — — 4 on EDGAR
Jun 9, 2026 Simson Jake Insider grant 19,475 — — 4 on EDGAR
Jun 9, 2026 Bowden Christopher Insider grant 19,475 — — 4 on EDGAR
Jun 9, 2026 POWELL MICHAEL Insider grant 19,475 — — 4 on EDGAR
Jun 9, 2026 Robertson Scott M. Insider grant 19,475 — — 4 on EDGAR
Jun 9, 2026 Haviland Kate Insider grant 19,475 — — 4 on EDGAR
May 21, 2026 Hyep Ivan Chief Financial Officer exercise 9,200 $3.79 $34,866 4 on EDGAR
May 18, 2026 Mazumdar Claire Chief Executive Officer exercise 15,000 $3.79 $56,847 4 on EDGAR
May 15, 2026 Cohlhepp Ryan President and COO exercise 8,000 $3.79 $30,318 4 on EDGAR
May 8, 2026 Schelman William Chief Medical Officer grant 85,000 — — 4 on EDGAR
Apr 27, 2026 Raben David Chief Medical Officer exercise 5,500 $3.79 $20,844 4 on EDGAR
Apr 21, 2026 Hyep Ivan Chief Financial Officer exercise 9,200 $3.79 $34,866 4 on EDGAR
Apr 16, 2026 Mazumdar Claire Chief Executive Officer exercise 8,226 $4.44 $36,498 4 on EDGAR
Apr 15, 2026 Cohlhepp Ryan President and COO exercise 8,000 $3.79 $30,318 4 on EDGAR
Mar 25, 2026 Raben David Chief Medical Officer exercise 5,500 $3.79 $20,844 4 on EDGAR
Mar 23, 2026 Hyep Ivan Chief Financial Officer exercise 9,200 $3.79 $34,866 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query BCAX context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access